From tissue-specific to tissue-agnostic: HER2 overexpression and the rise of antibody-drug conjugates

From tissue-specific to tissue-agnostic: HER2 overexpression and the rise of antibody-drug conjugates

The growing importance of HER2 expression as a biomarker across multiple cancers is largely driven by advances in HER2-directed antibody-drug conjugates. The recent approval of trastuzumab deruxtecan (T-DXd) as a tumor-agnostic therapy has revolutionized treatment strategies for HER2-overexpressed t...

Full description

Saved in:
Bibliographic Details
Main Authors: Heidi C. Ko, Kyle C. Strickland, Dana Jaggessarsingh, Alicia Dillard, Michelle Green, Erin Newburn, Tiffany Sellaro, Jonathan L. Klein, Brian Caveney, Marcia Eisenberg, Eric A. Severson, Shakti Ramkissoon, Rebecca A. Previs, Anis Toumeh
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Oncology
Subjects:
HER2 overexpression
ERBB2 amplification
pan-tumor testing
antibody-drug conjugate
next-generation sequencing
tissue stewardship
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1565872/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2025.1565872/full

Similar Items